Regenerative Medicine Pushes Toward Made-to-Match Organs and Fewer Transplant Barriers

A new wave of regenerative medicine research is attacking the organ shortage from several directions at once: 3D bioprinting, lab-grown tissue and technologies designed to overcome blood-type incompatibility. In the U.S., ARPA-H has launched a major program aimed at producing personalized, immune- and blood-type-matched organs on demand, while researchers have already demonstrated enzymatic conversion of donor kidneys toward universal blood group O in human decedent models. The technologies are not yet replacements for conventional transplantation, but several pieces of the longer-term pathway are moving from laboratory concepts toward translational testing.

ARTICLE

For patients waiting for an organ transplant, the central problem is brutally simple: there are not enough suitable organs.

In the United States alone, more than 100,000 people are waiting for an organ transplant at any given time, according to the Health Resources and Services Administration.

The conventional solution depends on finding a donor organ that is compatible with the recipient. That process is constrained not only by the number of available organs, but also by factors such as blood type, immune compatibility, organ size and medical urgency.

Regenerative medicine is now trying to change that equation.

Rather than simply making better use of donated organs, researchers are working toward technologies that could manufacture replacement tissue, grow functional organ structures and modify existing donor organs so that more patients can receive them.

Three developments illustrate how that strategy is taking shape: advanced 3D bioprinting, lab-grown organ constructs and biological methods for overcoming the ABO blood-type barrier.

3D Bioprinting Is Moving Beyond Simple Tissue Scaffolds

3D bioprinting uses living cells, biomaterials and bioactive components to build biological structures layer by layer.

Unlike conventional 3D printing with plastics or metals, the objective is not simply to reproduce an object’s shape. Researchers must create an environment in which living cells survive, organize themselves and eventually perform the functions expected of the tissue.

Recent reviews published in 2026 describe progress across tissues including bone, cartilage, skin and cardiac structures, while also highlighting continuing problems with vascularization, maturation, manufacturing consistency and regulatory approval.

That distinction is important.

Printing something that looks like a human organ is considerably easier than producing one that can survive after transplantation and perform all of the organ’s biological functions.

A kidney, for example, needs an intricate network of blood vessels and specialized cells capable of filtering blood and regulating fluid and electrolyte balance. A liver must perform hundreds of metabolic functions. A heart must contract continuously while maintaining its electrical and mechanical organization.

The closer researchers get to organ-scale structures, the more difficult those biological requirements become.

The Vascularization Problem Remains One of the Biggest Obstacles

One of the fundamental challenges is supplying engineered tissue with blood.

Cells deep inside a large tissue construct cannot survive indefinitely without access to oxygen and nutrients. A transplanted organ therefore needs a vascular network capable of carrying blood throughout the structure and connecting with the recipient’s circulation.

A 2026 review specifically examining microvascular engineering in bioprinting identified the creation of perfusable microvascular networks and their integration with the host as major unresolved challenges.

Researchers are responding with increasingly sophisticated printing approaches.

A 2026 study, for example, described a 3D-bioprinted tissue approach incorporating heterogeneous cell populations and flexible, perfusable vessel structures. The work illustrates the direction of the field: rather than printing a uniform mass of cells, researchers are attempting to reproduce the different cell types, structures and circulation pathways that make living tissue function.

These developments matter because vascularization is not an optional feature that can simply be added at the end. It is one of the requirements that determines whether a large engineered tissue can remain alive.

Organoids Add Another Layer of Biological Complexity

3D bioprinting is also converging with organoids—small, self-organizing cellular structures that reproduce some characteristics of real organs.

Organoids are not miniature replacement organs. Instead, they can reproduce selected aspects of organ architecture and function and are increasingly used for disease modeling, drug testing and regenerative medicine.

A 2026 review in Regenerative Biomaterials examined the convergence of organoids and 3D bioprinting, describing applications ranging from patient-derived tumor models to engineered bone, cartilage, cardiac and skin constructs. It also emphasized that regenerative applications remain at different stages of clinical translation.

The combination is potentially powerful.

Bioprinting provides spatial control over where cells and biomaterials are placed. Organoids provide biological organization that can be difficult to reproduce simply by depositing cells into a predetermined shape.

The long-term goal is to combine those capabilities into increasingly functional tissue.

The U.S. Is Funding a Push Toward On-Demand Organs

One of the clearest signs that organ biofabrication is becoming a strategic research priority comes from the U.S. Advanced Research Projects Agency for Health, or ARPA-H.

Its PRINT program—Personalized Regenerative Immunocompetent Nanotechnology Tissue—aims to develop personalized, on-demand organs using a patient’s own cells or cells from a biobank.

The program is targeting organs including kidneys, hearts and livers, with the objective of producing tissue that is matched to the patient’s immune system and blood type and could ultimately reduce the need for lifelong immunosuppressive medication.

In January 2026, ARPA-H announced the teams receiving awards under the program, including researchers from Carnegie Mellon University, Wake Forest University, the Wyss Institute at Harvard, UC San Diego and UT Southwestern Medical Center.

But PRINT is a research and development program, not evidence that hospitals can currently print transplantable kidneys or hearts on demand.

Its technical roadmap includes generating the necessary cell types, scaling their production and developing organ biofabrication and testing methods.

That means the program is trying to solve the manufacturing problem before a fully bioprinted replacement organ can become routine medicine.

Blood Type May Become a Less Rigid Transplant Barrier

There is another way to increase the number of usable donor organs: change the organ rather than waiting for a perfectly matched recipient.

The ABO blood-group system is one of the fundamental compatibility barriers in transplantation. Donor organs carrying blood-group antigens that are targeted by the recipient’s antibodies can trigger severe immune reactions.

Researchers have been developing enzymes capable of removing these blood-group markers from the surface of blood vessels inside donor organs.

In 2024, researchers demonstrated that two enzymes could remove approximately 80% of blood-group A antigens from human kidneys during machine perfusion, converting the organs toward a blood-group-O state in laboratory testing.

The significance is straightforward: if an organ can be converted into a form that is compatible with a wider range of recipients, some organs that would otherwise face a blood-type mismatch could potentially become usable.

A Converted Kidney Has Already Reached a Human Decedent Model

The research progressed further in 2025 and 2026.

In a study published in Nature Biomedical Engineering, researchers enzymatically converted a blood-group-B kidney toward type O and transplanted it into a brain-dead recipient with a high level of anti-B antibodies.

The converted kidney survived for 63 hours without hyperacute rejection—the immediate and severe immune reaction that can destroy an incompatible organ. Blood-group B antigens began to reappear within 48 hours, however, showing that the approach still has important limitations.

This was not a conventional clinical transplant in a living patient.

It was a human decedent model, an important research step that allows scientists to evaluate an intervention under physiological conditions without exposing a living transplant recipient to an unproven technique.

That distinction matters when assessing how close the technology is to routine clinical use.

The Goal Is Bigger Than Blood-Type Matching

The emerging technologies are beginning to converge around a broader concept: making transplantable tissue less dependent on the limitations of traditional donor matching.

ARPA-H’s PRINT program is approaching the problem from the manufacturing side, aiming to create organs that are personalized for individual recipients.

Enzymatic blood-group conversion approaches the problem from the compatibility side, attempting to modify existing donor organs so that they can cross one of the barriers that restricts transplantation.

Bioprinting and organoid research attacks the biological supply problem by trying to manufacture living tissue rather than relying entirely on donated organs.

Each approach solves a different part of the same problem.

Why a Fully Printed Organ Is Still Difficult

Despite the rapid progress, a printable organ is not yet equivalent to a transplantable organ.

Researchers still need to reproduce complex vascular networks, achieve functional maturation, maintain cell viability throughout large structures, establish reliable manufacturing processes and demonstrate long-term safety.

Immune rejection also remains a central issue, particularly when the cells used to build an organ are not genetically matched to the recipient.

A 2026 review of bioprinted organoids emphasized that regenerative applications currently span very different levels of maturity—from clinically relevant patient-derived models to preclinical proof-of-concept tissue engineering.

This is why the most realistic near-term progress may occur through specific tissues and partial biological functions, rather than immediately replacing entire organs.

From Donor Shortage to Organ Manufacturing

The most important change underway in regenerative medicine is therefore not that scientists have already solved transplantation.

They have not.

The change is that the organ shortage is increasingly being treated as an engineering problem with multiple possible solutions.

One research team can work on printing vascularized tissue. Another can develop organoids capable of reproducing specialized biological functions. Another can engineer cells that are less visible to the immune system. Another can modify donor organs to overcome blood-type incompatibility.

ARPA-H’s PRINT program is explicitly designed around this convergence, bringing cell manufacturing, biofabrication and safety testing into a single translational effort.

If those technologies eventually mature together, the transplant system could become less dependent on finding the perfect organ for the perfect recipient.

The ultimate vision is more ambitious: an organ supply that can be engineered, matched and manufactured rather than simply donated.

That future remains experimental. But with bioprinting advancing, organoid engineering becoming more sophisticated and blood-type conversion reaching human research models, the pathway from regenerative biology to transplantation is becoming increasingly concrete.

Most Searched 5 FAQs

1. Can 3D printers make human organs?

Researchers can 3D-bioprint living tissues and increasingly complex biological constructs, but fully functional, transplantable organs such as kidneys and hearts are not yet routinely produced for patients. Vascularization, maturation, immune compatibility and manufacturing remain major challenges.

2. What is 3D bioprinting used for in medicine?

3D bioprinting is being investigated for tissue engineering, regenerative medicine, disease modeling, drug testing and patient-specific biological constructs. Current research includes skin, bone, cartilage, cardiac tissue and organoid-based systems.

3. Can a donor kidney’s blood type be changed?

Researchers have demonstrated that enzymes can remove blood-group A or B antigens from donor kidneys during machine perfusion, converting them toward universal blood group O. The approach has progressed to human decedent research but is not yet routine clinical transplantation.

4. What is the PRINT organ program?

PRINT is an ARPA-H program seeking to develop personalized, on-demand bioprinted organs that are matched to a patient’s immune system and blood type. It is currently a research and development effort, not a hospital service for producing transplant organs.

5. Will 3D-printed organs eliminate transplant waiting lists?

They could eventually expand the supply of transplantable tissues and organs, but there is no evidence yet that bioprinting can eliminate transplant waiting lists. The technology still faces substantial biological, manufacturing and regulatory challenges.